About US
Contact us
-
Agalimmune Ltd Founded to Develop Immunotherapeutics for CancerAgalimmune Ltd, a biopharmaceutical company, has been created to develop innovative immunotherapeutics for the treatment of cancer, with a focus on solid tumours. The new company has been founded by a2013/11/27
-
Janssen obtains FDA approval for Olysio combination therapy for hepatitis C treatmentJanssen Therapeutics has received approval from the US Food and Drug Administration (FDA) for an NS3/4A protease inhibitor, Olysio (simeprevir), to treat chronic hepatitis C infection as part of an an2013/11/27
-
ViiV Healthcare obtains European positive opinion for HIV drug TivicayEuropean Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the marketing authorisation of ViiV Healthcare's Tivicay (dolutegravir) in com2013/11/26
-
Ophthalmology Therapeutics Market: India and China to Lead Modest GrowthThe ophthalmology therapeutics market for Dry Eye Syndrome (DES) and glaucoma in four Asia-Pacific (APAC) countries — India, Australia, China and Japan — will increase from $2.4 billion in 2012 to $3.2013/11/26
-
Genzyme gets Health Canada approval for multiple sclerosis drug AubagioSanofi firm Genzyme has received approval from Health Canada for its once-daily drug Aubagio (teriflunomide) 14mg as monotherapy to treat patients with relapsing remitting multiple sclerosis (RRMS).2013/11/25
-
CPhI Worldwide 2013 Hosted more than 34,000 Global Pharma Professionals with Expanded Content and First Annual ReportCPhI Worldwide, organised by UBM Live, celebrates the closing of its most successful show to date with pre-audit figures estimating more than 34,000 attendees and 2200 exhibitors. Held in Frankfurt, t2013/11/25
-
Q Therapeutics gets FDA orphan drug status for Q-Cells to treat ALS patientsUS-based biotechnology firm Q Therapeutics has received orphan drug designation from the US Food & Drug Administration (FDA) for its Q-Cells product (human glial restricted progenitor cells and th2013/11/22
-
Pfizer whacks plant as generics eat salesPfizer has completely remade itself in the face of patent expirations for blockbusters likeLipitor. The drugmaker last year sold its nutrition unit toNestlé, and this year it finished the sell-off of2013/11/22
-
FDA Should Take Action on ‘Unfeasible Guidances’ to Help Boost Stagnant US Antibiotics MarketWith a diminishing antibiotics pipeline and one of the primary market needs lying in the availability of effective antibiotics for hospital-acquired pneumonia, FDA needs to take serious action to allo2013/11/21
-
GSK cashing in one-third of its stake in South Africa's AspenIf you take a big bet on an up-and-coming pharmaceutical maker and you turn out to be right, you should be able to reap some profit from your investment. That's what GlaxoSmithKline ($GSK) intends to2013/11/21